You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

First RSV vaccine trial for infants offers significant results

Results from a phase 3 trial evaluating AstraZeneca and Sanofi’s jointly developed treatment nirsevimab – the first investigational long-acting antibody, designed to protect all infants from respiratory syncytial virus (RSV), with a single dose – have produced significant findings.